PARP1 impact on DNA repair of platinum adducts: Preclinical and clinical read-outs

Lung Cancer

Volumn 80, Issue 2, 2013, Pages 216-222

  Olaussen, Ken A ^a,b,c   Adam, Julien ^a,b,c   Vanhecke, Elsa ^a,b,c   Vielh, Philippe ^b   Pirker, Robert ^d   Friboulet, Luc ^a,b,c   Popper, Helmut ^e   Robin, Angélique ^a,b,c   Commo, Fréderic ^a,b,c   Thomale, Jürgen ^f   Kayitalire, Louis ^g   Filipits, Martin ^d   Le Chevalier, Thierry ^b   André, Fabrice ^a,b,c   Brambilla, Elisabeth ^h   Soria, Jean Charles ^a,b,c  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^g Tevapharm Inc   (United States)

^h HÔPITAL MICHALLON   (France)

Author keywords

Adjuvant chemotherapy; CDDP; Cisplatin; ERCC1; IALT bio; Immunohistochemistry; Lung cancer; MSH2; NSCLC biomarkers; PARP1

Indexed keywords

CISPLATIN; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1;

ARTICLE; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DNA ADDUCTS; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MUTS HOMOLOG 2 PROTEIN; PHENANTHRENES; PHTHALIMIDES; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS;

EID: 84875895743     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.01.014     Document Type: Article

References (18)

1. Loeb L.A. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer 2011, 11:450-457.
2. Bartkova J., Horejsi Z., Koed K., Krämer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
3. Kamal N.S., Soria J.C., Mendiboure J., Planchard D., Olaussen K.A., Rousseau V., et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 2010, 16:1206-1215.
4. Olaussen K.A., Dunant A., Fouret P., Brambilla E., André F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
5. Parsons J.L., Dianova I.I., Allinson S.L., Dianov G.L. Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts. FEBS J 2005, 272:2012-2021.
6. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
7. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
8. Clark C.C., Weitzel J.N., O'Connor T.R. Enhancement of synthetic lethality via combinations of ABT-888 (a PARP inhibitor) and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther 2012, 11:1948-1958.
9. Fong P.C., Yap T.A., Boss D.S., Carden C.P., Mergui-Roelvink M., Gourley C., et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010, 28:2512-2519.
10. Guggenheim E.R., Ondrus A.E., Movassaghi M., Lippard S.J. Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. Bioorg Med Chem 2008, 16:10121-10128.
11. Guggenheim E.R., Xu D., Zhang C.X., Chang P.V., Lippard S.J. Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA. Chembiochem 2009, 10:141-157.
12. Liedert B., Pluim D., Schellens J., Thomale J. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 2006, 34:e47.
13. Dunant A., Pignon J.P., Le Chevalier T. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial. Clin Cancer Res 2005, 11:5017s-5021s.
14. Filipits M., Pirker R., Dunant A., Lantuejoul S., Schmid K., Huynh A., et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007, 25:2735-2740.
15. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
16. Friboulet L., Barrios-Gonzales D., Commo F., Olaussen K.A., Vagner S., Adam J., et al. Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin Cancer Res 2011, 17:5562-5572.
17. Lima L.M., de Souza L.R., da Silva T.F., Pereira C.S., Guimarães A.L., de Paula A.M., et al. DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors. Histopathology 2012, 60:489-496.
18. Pierceall W.E., Olaussen K.A., Rousseau V., Brambilla E., Sprott K.M., Andre F., et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 2012, 23:2245-2252.